SI1740698T1 - Rekombinantno modificiran plazmin - Google Patents

Rekombinantno modificiran plazmin

Info

Publication number
SI1740698T1
SI1740698T1 SI200531131T SI200531131T SI1740698T1 SI 1740698 T1 SI1740698 T1 SI 1740698T1 SI 200531131 T SI200531131 T SI 200531131T SI 200531131 T SI200531131 T SI 200531131T SI 1740698 T1 SI1740698 T1 SI 1740698T1
Authority
SI
Slovenia
Prior art keywords
domain
recombinantly modified
terminal
human plasminogen
polypeptide
Prior art date
Application number
SI200531131T
Other languages
English (en)
Inventor
Jennifer Audrey Hunt
Valery Novokhatny
Original Assignee
Talecris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1740698(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Talecris Biotherapeutics Inc filed Critical Talecris Biotherapeutics Inc
Publication of SI1740698T1 publication Critical patent/SI1740698T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200531131T 2004-04-22 2005-04-21 Rekombinantno modificiran plazmin SI1740698T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56447204P 2004-04-22 2004-04-22
EP05737862A EP1740698B1 (en) 2004-04-22 2005-04-21 Recombinantly modified plasmin
PCT/US2005/013562 WO2005105990A2 (en) 2004-04-22 2005-04-21 Recombinantly modified plasmin

Publications (1)

Publication Number Publication Date
SI1740698T1 true SI1740698T1 (sl) 2010-11-30

Family

ID=34982338

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531131T SI1740698T1 (sl) 2004-04-22 2005-04-21 Rekombinantno modificiran plazmin

Country Status (28)

Country Link
US (2) US8034913B2 (sl)
EP (2) EP1740698B1 (sl)
JP (1) JP5026254B2 (sl)
KR (1) KR101161819B1 (sl)
CN (2) CN1961070A (sl)
AT (1) ATE476502T1 (sl)
AU (1) AU2005238464B2 (sl)
BR (1) BRPI0510063B8 (sl)
CA (1) CA2563675C (sl)
CY (1) CY1111650T1 (sl)
DE (1) DE602005022692D1 (sl)
DK (1) DK1740698T3 (sl)
EA (1) EA010784B1 (sl)
ES (2) ES2349555T3 (sl)
HK (3) HK1099341A1 (sl)
HR (1) HRP20100568T1 (sl)
IL (1) IL178343A (sl)
MA (1) MA28590B1 (sl)
MX (1) MXPA06012236A (sl)
NO (1) NO338542B1 (sl)
NZ (1) NZ550250A (sl)
PL (2) PL1740698T3 (sl)
PT (2) PT2246417E (sl)
RS (1) RS51623B (sl)
SI (1) SI1740698T1 (sl)
TN (1) TNSN06332A1 (sl)
WO (1) WO2005105990A2 (sl)
ZA (1) ZA200608498B (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070004706A (ko) 2004-02-11 2007-01-09 바이오렉스 인코포레이티드 개구리밥에서의 플라스미노겐 및 마이크로플라스미노겐의발현 방법
DK1740698T3 (da) 2004-04-22 2010-10-25 Talecris Biotherapeutics Inc Rekombinant modificeret plasmin
US8231869B2 (en) * 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
EP2220221B1 (en) * 2007-11-29 2014-12-31 Grifols Therapeutics Inc. Recombinantly modified plasmin
JP2011522538A (ja) 2008-06-04 2011-08-04 タレクリス・バイオセラピユーテイクス・インコーポレーテツド プラスミン製造のための組成物、方法およびキット
PT2403865E (pt) 2009-03-03 2015-11-18 Grifols Therapeutics Inc Métodos de preparação de plasminogénio
RU2564131C2 (ru) 2009-07-10 2015-09-27 ТромбоДженикс НВ Варианты плазминогена и плазмина
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
BR112013017172A2 (pt) 2011-01-05 2016-10-11 Thrombogenics Nv variantes de plasminogênio e plasmina
WO2013024074A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
WO2017101870A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
US11311607B2 (en) 2016-12-15 2022-04-26 Talengen International Limited Method for making glucagon and insulin restore normal balance
CN110167583A (zh) 2016-12-15 2019-08-23 泰伦基国际有限公司 一种治疗冠状动脉粥样硬化及其并发症的方法
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
CN108210895A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防动脉粥样硬化及其并发症的药物及其用途
EP4137713A4 (en) 2020-04-13 2024-05-08 Fcc Kk POWER TRANSMISSION DEVICE
KR20230005298A (ko) * 2020-05-11 2023-01-09 탈렌젠 인터내셔널 리미티드 척수성 근위축증의 치료 방법 및 약물
EP4251195A1 (en) 2020-11-25 2023-10-04 Grifols Worldwide Operations Limited Wound healing
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
WO2024018051A1 (en) 2022-07-22 2024-01-25 Grifols Worldwide Operations Limited Stable plasmin compositions for organ preservation and reconditioning

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ATE169030T1 (de) 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
EP0868535B9 (en) 1996-01-23 2007-05-09 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
NZ501774A (en) 1997-07-22 2002-02-01 Qiagen Genomics Inc Computer method and system for correlating known characteristics of biomolecules to molecular tags with unique molecular weights that are associated with the biomolecule
WO2000003726A1 (en) 1998-07-14 2000-01-27 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin
AU6200599A (en) 1998-09-29 2000-04-17 Leuven Research & Development Vzw Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of acomposition for the treatment of ischemic stroke
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
WO2001094366A1 (en) 2000-06-02 2001-12-13 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
US7445775B2 (en) * 2000-12-21 2008-11-04 Thromb-X Nv Yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
WO2003054232A2 (en) 2001-12-13 2003-07-03 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US20050124036A1 (en) 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
DK1740698T3 (da) 2004-04-22 2010-10-25 Talecris Biotherapeutics Inc Rekombinant modificeret plasmin
US8231869B2 (en) 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
EP2220221B1 (en) 2007-11-29 2014-12-31 Grifols Therapeutics Inc. Recombinantly modified plasmin

Also Published As

Publication number Publication date
MA28590B1 (fr) 2007-05-02
PT2246417E (pt) 2015-05-05
ES2534744T3 (es) 2015-04-28
CA2563675C (en) 2012-08-28
JP2007533327A (ja) 2007-11-22
EP2246417A1 (en) 2010-11-03
KR20070006918A (ko) 2007-01-11
EP2246417B1 (en) 2015-01-21
DK1740698T3 (da) 2010-10-25
EP1740698A2 (en) 2007-01-10
PT1740698E (pt) 2010-11-02
BRPI0510063B8 (pt) 2021-05-25
HK1175812A1 (en) 2013-07-12
CY1111650T1 (el) 2015-10-07
DE602005022692D1 (de) 2010-09-16
US20110318812A1 (en) 2011-12-29
EA200601950A1 (ru) 2007-02-27
PL1740698T3 (pl) 2011-01-31
NO20065050L (no) 2006-11-03
CA2563675A1 (en) 2005-11-10
BRPI0510063B1 (pt) 2020-03-17
IL178343A0 (en) 2007-02-11
HRP20100568T1 (hr) 2010-11-30
US8034913B2 (en) 2011-10-11
CN102660564B (zh) 2013-05-08
RS51623B (en) 2011-08-31
KR101161819B1 (ko) 2012-07-03
HK1099341A1 (en) 2007-08-10
WO2005105990A3 (en) 2006-01-12
NO338542B1 (no) 2016-09-05
IL178343A (en) 2010-11-30
JP5026254B2 (ja) 2012-09-12
ZA200608498B (en) 2008-07-30
ATE476502T1 (de) 2010-08-15
EP1740698B1 (en) 2010-08-04
NZ550250A (en) 2009-05-31
AU2005238464B2 (en) 2011-01-27
BRPI0510063A (pt) 2008-03-11
US8420079B2 (en) 2013-04-16
WO2005105990A2 (en) 2005-11-10
AU2005238464A1 (en) 2005-11-10
EA010784B1 (ru) 2008-10-30
CN1961070A (zh) 2007-05-09
TNSN06332A1 (en) 2008-02-22
CN102660564A (zh) 2012-09-12
MXPA06012236A (es) 2007-01-31
US20100304465A1 (en) 2010-12-02
ES2349555T3 (es) 2011-01-05
HK1150242A1 (en) 2011-11-11
PL2246417T3 (pl) 2015-06-30

Similar Documents

Publication Publication Date Title
HK1175812A1 (en) Recombinantly modified plasmin
NZ593837A (en) Recombinantly modified plasmin
Bode The structure of thrombin: a janus-headed proteinase
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
Hata et al. Domain II of m-calpain is a Ca2+-dependent cysteine protease
TW200733970A (en) Recombinantly modified plasmin
MX2009011179A (es) Variantes de enzimas asparaginasas y sus usos.
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
UA103215C2 (uk) Поліпептид з ксиланазною активністю
Sanchez et al. A novel fibrinolytic metalloproteinase, barnettlysin-I from Bothrops barnetti (Barnett s pitviper) snake venom with anti-platelet properties
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
AU3175197A (en) Recombinant blood-coagulation proteases
Hahn et al. Purification and characterization of a serine protease with fibrinolytic activity from Tenodera sinensis (praying mantis)
HUP0400458A2 (hu) Kobalaminkötő fehérjéket expresszáló transzgenikus növények
Oyama et al. Amino acid sequence of a thrombin like enzyme, elegaxobin, from the venom of Trimeresurus elegans (Sakishima-habu)
ATE345383T1 (de) Säugeradhäsionprotease
DE60336265D1 (de) Inhibitoren der enzymaktivität der endooligopeptidase a (eopa) und ihre verwendungen
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
Oyama et al. Amino acid sequence of a thrombin like enzyme, elegaxobin II, from the venom of Trimeresurus elegans (Sakishima-Habu)
WO2005037202A3 (en) Methods for modulating angiogenesis
WO2003085377A3 (en) Novel pancortin-pablo protein interactions and methods of use thereof